UroGen Pharma Ltd. (URGN)
Largest Insider Buys in Sector
URGN Stock Price History Chart
URGN Stock Performance
About UroGen Pharma Ltd.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma …
Insider Activity of UroGen Pharma Ltd.
Over the last 12 months, insiders at UroGen Pharma Ltd. have bought $0 and sold $543,940 worth of UroGen Pharma Ltd. stock.
On average, over the past 5 years, insiders at UroGen Pharma Ltd. have bought $264,948 and sold $344,244 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 160 shares for transaction amount of $2,096 was made by Schoenberg Mark (Chief Medical Officer) on 2021‑11‑18.
List of Insider Buy and Sell Transactions, UroGen Pharma Ltd.
| 2024-09-09 | Sale | Chief Medical Officer | 859 0.002% | $13.08 | $11,236 | -7.27% | ||
| 2024-09-09 | Sale | General Counsel | 1,521 0.0035% | $13.08 | $19,895 | -7.27% | ||
| 2024-06-10 | Sale | Chief Medical Officer | 5,153 0.0146% | $13.08 | $67,401 | +1.57% | ||
| 2024-03-18 | Sale | Chief Medical Officer | 12,000 0.0341% | $14.05 | $168,600 | -8.41% | ||
| 2024-02-01 | Sale | Chief Medical Officer | 3,789 0.0123% | $15.78 | $59,790 | -13.55% | ||
| 2024-02-01 | Sale | General Counsel | 4,993 0.0162% | $15.78 | $78,790 | -13.55% | ||
| 2024-01-31 | Sale | Chief Medical Officer | 3,789 0.0122% | $15.74 | $59,639 | -12.36% | ||
| 2024-01-31 | Sale | General Counsel | 4,993 0.0161% | $15.74 | $78,590 | -12.36% | ||
| 2023-08-31 | Sale | General Counsel | 3,800 0.0129% | $18.01 | $68,438 | -17.28% | ||
| 2023-01-31 | Sale | Chief Medical Officer | 1,900 0.0079% | $10.12 | $19,228 | +14.63% | ||
| 2023-01-31 | Sale | General Counsel | 1,636 0.0068% | $10.12 | $16,556 | +14.63% | ||
| 2022-10-31 | Sale | Chief Medical Officer | 258 0.0011% | $11.85 | $3,057 | -12.49% | ||
| 2022-08-31 | Sale | General Counsel | 3,606 0.0153% | $7.21 | $25,999 | +29.46% | ||
| 2022-07-31 | Sale | Chief Medical Officer | 259 0.0011% | $7.81 | $2,023 | |||
| 2022-04-30 | Sale | Chief Medical Officer | 254 0.001% | $6.62 | $1,681 | |||
| 2022-01-31 | Sale | Chief Executive Officer | 8,195 0.0356% | $7.58 | $62,118 | +5.96% | ||
| 2022-01-31 | Sale | Chief Medical Officer | 1,374 0.006% | $7.58 | $10,415 | +5.96% | ||
| 2022-01-31 | Sale | General Counsel | 414 0.0018% | $7.58 | $3,138 | +5.96% | ||
| 2022-01-31 | Sale | Chief Financial Officer | 331 0.0014% | $7.58 | $2,509 | +5.96% | ||
| 2022-01-26 | Sale | Chief Medical Officer | 111 0.0005% | $8.09 | $898 | +4.48% |
Insider Historical Profitability
| Schoenberg Mark | Chief Medical Officer | 145091 0.3438% | $10.82 | 3 | 28 | <0.0001% |
| Smith Jason Drew | General Counsel | 25226 0.0598% | $10.82 | 1 | 8 | <0.0001% |
| Barrett Elizabeth A. | Chief Executive Officer | 300985 0.7132% | $10.82 | 4 | 2 | <0.0001% |
| Henderson Molly | Chief Financial Officer | 5248 0.0124% | $10.82 | 1 | 2 | <0.0001% |
Institutional Investor Ownership
| RTW Investments, LP | $48.86M | 7.91 | 3.26M | +88.63% | +$22.96M | 0.73 | |
| RA Capital Management, L.P. | $46.25M | 7.49 | 3.08M | 0% | +$0 | 0.05 | |
| Great Point Partners | $39.31M | 6.37 | 2.62M | 0% | +$0 | 6.59 | |
| Menora Mivtachim Holdings Ltd | $34.55M | 5.59 | 2.3M | 0% | +$0 | 0.27 | |
| BlackRock | $25.75M | 4.17 | 1.72M | -0.14% | -$37,365.00 | <0.01 |